The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
No Access

Corneal and lenticular opacities in mentally retarded young adults treated with thioridazine and chlorpromazine

Published Online:https://doi.org/10.1176/ajp.139.9.1178

Of 18 mentally retarded institutionalized subjects who had received long-term, high-dose treatment primarily with thioridazine or chlorpromazine, 2 developed definite corneal and lenticular opacities and 2 had equivocal ocular changes. In view of this finding, the authors suggest that alternative treatment, including different neuroleptics, be considered with mentally retarded institutionalized subjects; when that is not possible, subjects should be given periodic evaluation, including annual slit-lamp examination.

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.